疑似非重症呼吸机相关性肺炎中立即与培养启动抗生素治疗的比较:一项前后对照研究(DELAVAP)
这项单中心前后对照研究纳入首次疑似非重症VAP(无需血管加压药的休克或重度ARDS)且行远端呼吸道采样患者,2019年采样后立即启动抗生素(44例),2022年培养阳性后启动(保守策略,43例)。主要终点为28天内无抗生素存活天数,两组相似(中位数18.0 vs 16.0天,p=0.50)。保守组抗生素适宜性更高(88.4% vs 63.6%,p=0.01),27.9%患者未接受抗生素。机械通气时长和28天死亡率无显著差异。作者认为结果可能归因于统计效能低,并提示可开展大型随机试验。
要点
- 疑似非重症VAP患者中,保守策略(培养阳性后启动抗生素)与立即策略的28天无抗生素存活天数相似(中位数18.0 vs 16.0天,p=0.50)。
- 保守组抗生素适宜性更高(88.4% vs 63.6%,p=0.01),且27.9%患者完全未接受抗生素。
- 两组28天无广谱抗生素存活天数无显著差异(p=0.53)。
- 机械通气时长(中位数9.0 vs 9.0天,p=0.65)和28天死亡率(HR 0.85,95%CI 0.4-2.0,p=0.71)无显著差异。
- 作者认为等待微生物确认未带来抗生素节省,可能归因于统计效能低,并提示可开展大型随机试验。
适用人群与场景
- 首次疑似非重症VAP、行远端呼吸道采样的连续患者;非重症定义为无需要血管加压药治疗的休克或无重度急性呼吸窘迫综合征。
处置流程与药物剂量
- 立即策略:呼吸道采样后立即启动抗生素治疗(2019年)。
- 保守策略:等待微生物培养阳性结果后启动抗生素治疗(2022年)。
研究设计与关键结果
- 单中心前后对照研究,纳入2019年立即策略44例和2022年保守策略43例。
- 主要终点28天内无抗生素存活天数:保守组中位数18.0天(四分位距0-21.0)vs 立即组16.0天(0-20.0),p=0.50。
- 28天内无广谱抗生素存活天数:两组无显著差异,p=0.53。
- 抗生素适宜性(有指征的必需抗生素或节省抗生素):保守组88.4% vs 立即组63.6%,p=0.01。
- 保守组27.9%患者完全未接受抗生素。
- 机械通气时长:保守组中位数9.0天(95%CI 6-19)vs 立即组9.0天(95%CI 6-24),p=0.65。
- 28天死亡率:HR 0.85(95%CI 0.4-2.0),p=0.71。
证据类型、等级与局限
- 证据类型:单中心前后对照研究。
- 局限:作者认为结果可能归因于统计效能低;作者提示可开展大型随机试验比较立即与保守抗生素策略。
对床旁实践的改变
- 在疑似非重症VAP患者中,等待微生物确认未减少抗生素使用天数,但抗生素适宜性更高,且27.9%患者可避免抗生素;作者认为这些发现似乎允许开展大型随机试验比较立即与保守策略。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Ventilator-associated pneumonia (VAP) is the leading nosocomial infection in critical care and is associated with adverse outcomes. When VAP is suspected, starting antibiotic therapy (AT) immediately after pulmonary sampling may expose uninfected patients to unnecessary treatment, whereas waiting for bacteriological confirmation may delay AT in infected patients. As no robust data exist to choose between these strategies, the decision must balance the pre-test diagnostic probability, clinical severity, and risk of antimicrobial resistance. The objective of this study in patients with suspected non-severe VAP was to compare immediate AT started after sampling to conservative AT upon receipt of positive microbiological results. The outcomes were antibiotic sparing, AT suitability, and patient outcomes.
METHODS: This single-center, before-after study included consecutive patients who underwent distal respiratory sampling for a first suspected non-severe VAP episode (no shock requiring vasopressor therapy or severe acute respiratory distress syndrome). AT was started immediately after sampling in 2019 and upon culture positivity in 2022 (conservative strategy). The primary outcome was the number of days alive without AT by day 28. The secondary outcomes were mechanical ventilation duration, day-28 mortality, and AT suitability (active necessary AT or spared AT).
RESULTS: The immediate and conservative strategies were applied in 44 and 43 patients, respectively. Conservative and immediate AT were associated with similar days alive without AT (median [interquartile range], 18.0 [0-21.0] vs. 16.0 [0-20.0], p = 0.50) and without broad-spectrum AT (p = 0.53) by day 28. AT was more often suitable in the conservative group (88.4% vs. 63.6%, p = 0.01), in which 27.9% of patients received no AT at all. No significant differences were found for mechanical ventilation duration (median [95%CI], 9.0 [6-19] vs. 9.0 [6-24] days, p = 0.65) or day-28 mortality (hazard ratio [95%CI], 0.85 [0.4-2.0], p = 0.71).
CONCLUSION: In patients with suspected non-severe VAP, waiting for microbiological confirmation was not associated with antibiotic sparing, compared to immediate AT. This result may be ascribable to low statistical power. AT suitability was better with the conservative strategy. None of the safety outcomes differed between groups. These findings would seem to allow a large, randomized trial comparing immediate and conservative AT strategies.
参考来源
- Martin M, Forveille S, Lascarrou JB, et al. Immediate vs. culture-initiated antibiotic therapy in suspected non-severe ventilator-associated pneumonia: a before-after study (DELAVAP). Ann Intensive Care. 2024. PMID: 38411756. doi:10.1186/s13613-024-01243-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。